Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2817387/0/en/Travere-Therapeutics-Announces-Licensing-Agreement-with-Renalys-Pharma-to-Develop-and-Commercialize-Sparsentan-in-Japan-South-Korea-Taiwan-and-Southeast-Asian-Nations.html

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ:TVTX) announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia. Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.

Read more at globenewswire.com

Related news for (TVTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.